When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

A pregnant, primiparous 32-year-old woman at 28 weeks’ gestation presented for a routine prenatal visit. Blood work showed thrombocytopenia with platelet count of 60 (reference range 130–380) × 109/L.